Bibliography
- Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007;12(11-12):479-86
- Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19(5):330-8
- Stockley RA. Proteases and antiproteases. Novartis Found Symp 2001;234:189-99
- Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008;12(4):361-7
- Bernstein PR, Edwards PD, Williams JC. Inhibitors of human leukocyte elastase. Prog Med Chem 1994;31:59-120
- Tremblay GM, Janelle MF, Bourbonnais Y. Anti-inflammatory activity of neutrophil elastase inhibitors. Curr Opin Investig Drugs 2003;4:556-65
- Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002;11:965-80
- Kawabata K, Hagio T, Matsuoka S. Pharmacological profile of a specific neutrophil elastase inhibitor, Sivelestat sodium hydrate. Nippon Yakurigaku Zasshi 2003;122(2):151-60
- Shime N, Hashimoto S. Sivelestat sodium for aspiration-related acute lung injury: a review and analysis of published case reports. Masui 2006;55(6):735-41
- Luisetti M, Sturani C, Sella D, MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996;9(7):1482-6
- A dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at three dose levels to patients with chronic obstructive pulmonary disease (COPD) on treatment with tiotropium. Available from: http://clinicaltrials.gov/ct2/show/NCT00949975
- Efficacy and safety of twice daily 60 mg AZD9668 in COPD for 12 weeks in patients on background budesonide/formoterol. Available from: http://clinicaltrials.gov/ct2/show/NCT01023516
- AstraZeneca AB. 2-pyridone derivatives as neutrophil elastase inhibitors and their use. WO2005026123; 2005
- Baugh RJ, Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry 1976;15:836-41
- AstraZeneca AB. 2-pyridone derivatives as inhibitors of neutrophil elastase. WO2004043924; 2004
- AstraZeneca UK Ltd. Combination therapy for the treatment of respiratory diseases. WO2008053199; 2008
- Sanfridson A, Ottosson T, Ekhol K, AZD9668: pharmacological characterisation of a novel oral inhibitor of neutrophil elastase (NE). ERS Annual Congress, Barcelona; 2010. p. 5150
- Gunawardena K, Gullstrand H, Perrett J. Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD. ERS Annual Congress, Barcelona; 2010. p. 1163
- Snell N, Stockley R, Perrett J, Gunawardena K. Efficacy and safety of AZD9668, an oral neutrophil elastase inhibitor, in idiopathic bronchiectasis. ERS Annual Congress, Barcelona; 2010. p. 375